Lineage Cell Therapeutics, Inc.·4

Dec 19, 9:55 PM ET

Samuel George A. III 4

4 · Lineage Cell Therapeutics, Inc. · Filed Dec 19, 2025

Insider Transaction Report

Form 4
Period: 2025-12-19
Samuel George A. III
General Counsel and Secretary
Transactions
  • Award

    Common Shares

    2025-12-19+1,73527,555 total
  • Tax Payment

    Common Shares

    2025-12-19$1.68/sh65$10927,490 total
Footnotes (3)
  • [F1]Shares earned by the Reporting Person upon the vesting of a portion of restricted stock units ("RSUs") granted to the Reporting Person on February 11, 2022 the vesting of which was subject to the achievement of certain performance conditions. RSUs are settled in common shares on a one-for-one basis.
  • [F2]Does not include RSUs that may be settled in the issuer's common shares that have not vested as of the date hereof nor common shares that may be acquired upon the exercise of certain stock options outstanding as of the date hereof.
  • [F3]Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 1,735 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4